Avidity Partners 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 55 US equity positions worth $498.8m in its Q2 2025 13F filing. The largest position was CGON at 7.8% of the reported book, followed by BSX and NTRA. Against the Q1 2025 filing, it opened 16 new positions, added to 17 and reduced 13 among the top 50 holdings.
What did Avidity Partners own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 7.8% | $39.0m | 1,499,942 | 53% | added |
| 2 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 6.9% | $34.6m | 321,800 | -4% | reduced |
| 3 | NTRA NATERA INC | Healthcare | 6.8% | $33.7m | 199,300 | 67% | added |
| 4 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 6.5% | $32.5m | 1,742,902 | 1% | added |
| 5 | EXK EXACT SCIENCES CORP | Basic Materials | 3.8% | $18.9m | 355,000 | 1% | added |
| 6 | THC TENET HEALTHCARE CORP | Healthcare | 3.7% | $18.7m | 106,000 | 47% | added |
| 7 | DXCM DEXCOM INC | Healthcare | 3.7% | $18.4m | 210,500 | 17% | added |
| 8 | DHR DANAHER CORPORATION | Healthcare | 3.6% | $17.7m | 89,700 | 102% | added |
| 9 | HNGE HINGE HEALTH INC | Healthcare | 3.3% | $16.7m | 322,344 | – | new |
| 10 | ISRG INTUITIVE SURGIVAL INC | Healthcare | 3.0% | $14.7m | 27,100 | – | new |
| 11 | GMAB GENMAB A/S | Healthcare | 2.7% | $13.4m | 650,000 | – | new |
| 12 | RGEN REPLIGEN CORP | Healthcare | 2.7% | $13.2m | 106,500 | – | new |
| 13 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 2.4% | $12.0m | 29,600 | 91% | added |
| 14 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 2.3% | $11.6m | 689,500 | 43% | added |
| 15 | JBIO JADE BIOSCIENCES INC | 2.3% | $11.3m | 1,127,186 | – | new | |
| 16 | PHAT PHATHOM PHARMACEUTICALS INC | 2.0% | $10.2m | 1,064,500 | 33% | added | |
| 17 | UNH UNITEDHEALTH GROUP INC | Healthcare | 2.0% | $10.0m | 32,000 | -37% | reduced |
| 18 | MCK MCKESSON CORP | Healthcare | 2.0% | $9.9m | 13,500 | – | new |
| 19 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 2.0% | $9.9m | 94,500 | 23% | added |
| 20 | COR CENCORA INC | Healthcare | 2.0% | $9.8m | 32,800 | -17% | reduced |
| 21 | HQY HEALTHEQUITY INC | Healthcare | 1.9% | $9.6m | 92,000 | 18% | added |
| 22 | EHC ENCOMPASS HEALTH CORP | Healthcare | 1.8% | $9.1m | 74,000 | – | new |
| 23 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.7% | $8.4m | 228,600 | 7% | added |
| 24 | AKERO THERAPEUTICS INC | 1.4% | $7.2m | 134,000 | 135% | added | |
| 25 | OMDA OMADA HEALTH INC | Healthcare | 1.4% | $7.1m | 390,600 | – | new |
| 26 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.4% | $7.0m | 409,400 | -42% | reduced |
| 27 | HUM HUMANA INC | Healthcare | 1.4% | $6.7m | 27,600 | -66% | reduced |
| 28 | CATX PERSPECTIVE THERAPEUTICS INC | 1.3% | $6.4m | 1,858,596 | -15% | reduced | |
| 29 | OGN ORGANON & CO | Healthcare | 1.2% | $6.2m | 640,000 | 20% | added |
| 30 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.2% | $6.0m | 140,000 | 87% | added |
| 31 | INSM INSMED INC | Healthcare | 1.2% | $5.9m | 59,000 | -45% | reduced |
| 32 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.2% | $5.8m | 19,000 | – | new |
| 33 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.1% | $5.6m | 154,000 | -52% | reduced |
| 34 | CNTX CONTEXT THERAPEUTICS INC | 1.0% | $4.9m | 7,477,255 | 0% | held | |
| 35 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.8% | $3.9m | 352,124 | 0% | held |
| 36 | IMUX IMMUNIC INC | Healthcare | 0.8% | $3.9m | 5,615,811 | 26% | added |
| 37 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.8% | $3.8m | 268,000 | – | new |
| 38 | DOCS DOXIMITY INC | Healthcare | 0.7% | $3.7m | 60,000 | -51% | reduced |
| 39 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.7% | $3.4m | 107,891 | -53% | reduced |
| 40 | VRNA VERONA PHARMA PLC | 0.6% | $3.2m | 33,800 | – | new | |
| 41 | UNIQURE NV | 0.6% | $2.9m | 207,000 | -38% | reduced | |
| 42 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.6% | $2.8m | 65,000 | – | new |
| 43 | SOLENO THERAPEUTICS INC | 0.5% | $2.7m | 32,000 | 0% | held | |
| 44 | CAH CARDINAL HEALTH INC | Healthcare | 0.5% | $2.5m | 15,000 | – | new |
| 45 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.5% | $2.4m | 140,000 | – | new |
| 46 | KEZAR LIFE SCIENCES INC | 0.5% | $2.3m | 502,600 | 0% | held | |
| 47 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.4% | $2.2m | 232,000 | – | new |
| 48 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.4% | $1.8m | 39,000 | – | new |
| 49 | ARVN ARVINAS INC | Healthcare | 0.4% | $1.8m | 243,162 | -41% | reduced |
| 50 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.3% | $1.4m | 150,000 | -84% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.